Table 3

Physician-rated risk scores (main analysis set)

Cohort A (switched from VKA to dabigatran)Cohort B (newly initiated on dabigatran or a VKA)
Total (n=4100)Dabigatran (n=3179)VKA (n=2186)Total (n=5365)
CHA2DS2-VASc score (category), n (%)
 High risk (≥2)3619 (88.3)2791 (87.8)1998 (91.4)4789 (89.3)
 Low/intermediate risk (<2)222 (5.4)262 (8.2)153 (7.0)415 (7.7)
 Not available259 (6.3)126 (4.0)35 (1.6)161 (3.0)
CHA2DS2-VASc score (result), n (%)
 013 (0.3)19 (0.6)14 (0.6)33 (0.6)
 1209 (5.1)243 (7.6)139 (6.4)382 (7.1)
 2529 (12.9)599 (18.8)400 (18.3)999 (18.6)
 3944 (23.0)759 (23.9)536 (24.5)1295 (24.1)
 4875 (21.3)643 (20.2)481 (22.0)1124 (21.0)
 5640 (15.6)404 (12.7)330 (15.1)734 (13.7)
 6362 (8.8)263 (8.3)150 (6.9)413 (7.7)
 7195 (4.8)85 (2.7)77 (3.5)162 (3.0)
 862 (1.5)25 (0.8)18 (0.8)43 (0.8)
 912 (0.3)13 (0.4)6 (0.3)19 (0.4)
 Not available259 (6.3)126 (4.0)35 (1.6)161 (3.0)
HAS-BLED score (category), n (%)
 High risk (≥3)2429 (59.2)925 (29.1)685 (31.3)1610 (30.0)
 Low risk (<3)1272 (31.0)2039 (64.1)1437 (65.7)3476 (64.8)
 Not available399 (9.7)215 (6.8)64 (2.9)279 (5.2)
HAS-BLED score (result), n (%)
 052 (1.3)166 (5.2)112 (5.1)278 (5.2)
 1386 (9.4)785 (24.7)553 (25.3)1338 (24.9)
 2834 (20.3)1088 (34.2)772 (35.3)1860 (34.7)
 31149 (28.0)634 (19.9)492 (22.5)1126 (21.0)
 4865 (21.1)223 (7.0)150 (6.9)373 (7.0)
 5313 (7.6)61 (1.9)39 (1.8)100 (1.9)
 682 (2.0)6 (0.2)4 (0.2)10 (0.2)
 718 (0.4)1 (0.0)1 (0.0)
 82 (0.0)
 Not available399 (9.7)215 (6.8)64 (2.9)279 (5.2)
  • VKA, vitamin K antagonist.